Omakase Lab 1 2018 – P&R Orphan Drugs

//Omakase Lab 1 2018 – P&R Orphan Drugs

Omakase Lab 1 2018 – P&R Orphan Drugs

In this report we identify the P&R situation in Spain of ODs approved by the European Commission between 2012-2016, and we analyse potential favourable ODs profiles for P&R approval in Spain, based on clinical, economic and institutional reimbursement variables.

Download file

2018-10-22T22:36:22+00:00September 19th, 2018|Omakase thought leadership Lab|

This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and the acceptance of our cookies policy, Click on the link for more information. ACEPTAR

Aviso de cookies